Reflection on Drug Safety and Foreign Manufacturing

Back in December 2007, Leroy Hubley faced an unimaginable loss when his wife and son both passed away within weeks. They had been taking heparin, a generic drug made in China, to manage a genetic kidney condition—a drug that turned out to be contaminated. This tragedy rattled Leroy’s trust in the pharmaceutical system and the FDA’s oversight. What was supposed to be a lifeline ended up taking their lives instead.

Unfortunately, Leroy and his family aren’t alone in this ordeal. The reliance on generic drugs manufactured abroad has led to serious issues over the years. Nearly two decades later, the heparin incident that claimed over 100 lives still looms large. Just this year, contaminated eye drops from India resulted in four deaths and harmed numerous others.

This troubling dependence on foreign-made generic drugs raises concerns not just for public health but also for national security. Recently, as chair of the U.S. Senate Select Committee on Aging, I led hearings focusing on the flaws in our drug procurement processes, which are particularly risky for vulnerable populations like older adults.

Currently, around 75% of essential medicines in the U.S. come from foreign manufacturers, especially from China and India. Shockingly, 83% of the top 100 generic drugs used in the U.S. do not use American-sourced active pharmaceutical ingredients. This means that the medicine cabinets of many American households likely contain drugs made overseas with ingredients that originate elsewhere.

Dr. George Ball, a respected academic, highlighted during our hearings how the FDA’s oversight shortcomings have allowed many of these foreign-active ingredients to be of inferior quality, sometimes even dangerous. His findings suggest that low-quality medications from countries like China and India not only risk ineffectiveness but could also pose serious health threats.

Manufacturing facilities overseas are not held to the same strict scrutiny as those in the U.S. In one hearing, Peter Baker, a former FDA inspector, shared alarming experiences from his trips to foreign plants. He recounted tales of falsified quality reports, irregular inspections, and unregistered facilities producing low-quality drugs. There were even instances where inspections were announced far in advance, allowing time for facilities to clean up their act before being checked.

These quality control issues represent an urgent hazard for everyone, but the even scarier reality lies in our heavy dependence on these foreign generic drugs. It’s sobering to think that if China or India decided to halt their drug exports, the U.S. would have no contingency plan in place to ensure that vital medicines remain available. People relying on Medicare or services from the Department of the Army could be at severe risk, particularly given that the bulk of foreign generic drugs are utilized by these groups. Essentially, we’re endangering lives while inadvertently supporting nations hostile to our interests.

Both China and India have previously limited exports of crucial materials. We’ve seen this happen before—like during the recent pandemic when India blocked pharmaceutical raw material exports. It’s a stark reminder of how reliant we’ve become on foreign supplies.

Adding to the concern, over 40% of the generic drugs in the U.S. are produced by only one FDA-approved manufacturer. If that supplier experiences issues, the FDA must scramble to find alternatives. This was evident in the recent shortage of the chemotherapy drug cisplatin, where unapproved substitutes from China had to be rushed to market, raising suspicions about their safety and efficacy.

Regrettably, the influence of China and India on our generic drug market continues to expand, as highlighted by testimonies at the hearings. If we don’t address these issues soon, we could face more unnecessary tragedies in the future. It’s high time we prioritize access to safe, quality medicines for everyone, including future generations.

I am committed to advocating for solutions that safeguard Americans, especially seniors, who depend on these vital drugs. The Aging Committee has hosted multiple hearings, and a report detailing actionable recommendations will be made public soon. I encourage everyone to be aware of these developments and advocate for meaningful change.